Beyond monotherapy: The synergistic potential of actinomycete-derived antibiotics with conventional drugs

The escalating crisis of antimicrobial resistance (AMR) has severely compromised the efficacy of conventional antibiotics, creating an urgent need for innovative therapeutic strategies. Combination therapy, particularly the use of synergistic drug pairings, has emerged as a powerful approach to overcome resistance, enhance therapeutic efficacy, and prolong the clinical lifespan of existing drugs. Actinomycetes, a phylum of bacteria renowned for their prolific production of bioactive secondary metabolites, have historically been a cornerstone of antibiotic discovery. This review explores the contemporary relevance of actinomycete-derived compounds, not as standalone monotherapies, but as critical partners in synergistic combinations with conventional antibiotics. We delve into the molecular and mechanistic underpinnings of synergy, categorizing interactions such as sequential pathway inhibition, enhancement of drug penetration, and inactivation of bacterial resistance determinants. A comprehensive synthesis of recent in vitro and in vivo experimental evidence is presented, highlighting successful combinations against high-priority pathogens like methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter baumannii. Furthermore, we discuss the clinical and translational relevance of these findings, while also addressing the current limitations, knowledge gaps, and methodological challenges in synergy research. By synthesizing the evidence, this review underscores the immense, yet underexplored, potential of actinomycete-derived natural products to revitalize our antibiotic arsenal and provides a roadmap for future research in this critical area.